Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.81 |
| ▸ | HTR2A | P28223 | 1/20 | 0.81 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.81 |
| ▸ | PARP1 | P09874 | 3/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5251886 | 0.99 | HTR1A (0.79) | HTR1AHTR2ATMEM97PARP1PARP2 | |
| SCHEMBL5250232 | 0.91 | HTR1A (0.84) | HTR1AHTR2ATMEM97PARP1ACHE | |
| Hydrochloric Acid SCHEMBL5250528 | 0.90 | HTR1A (0.82) | HTR1AHTR2ATMEM97PARP1ACHE | |
| Roluperidone SCHEMBL5252391 | 0.89 | HTR2A (1.00) | HTR1AHTR2ATMEM97PARP1ACHE | |
| SCHEMBL5248922 | 0.89 | HTR2A (0.81) | HTR1AHTR2ATMEM97PARP1PARP2 | |
| SCHEMBL5253797 | 0.89 | HTR1A (0.76) | HTR1AHTR2ATMEM97ACHERAB9A | |
| SCHEMBL5248309 | 0.89 | HTR1A (0.70) | HTR1AHTR2ATMEM97PARP1PARP2 | |
| Roluperidone SCHEMBL5248131 | 0.88 | HTR2A (0.98) | HTR1AHTR2ATMEM97ACHERAB9A | |
| Hydrochloric Acid SCHEMBL5249785 | 0.88 | HTR2A (0.79) | HTR1AHTR2ATMEM97PARP1ACHE | |
| Hydrochloric Acid SCHEMBL5247921 | 0.88 | HTR1A (0.75) | HTR1AHTR2ATMEM97ACHEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3135286-B1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA AND SYMPTOMS THEREOF | MINERVA NEUROSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230201184-A1 | COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA | MINERVA NEUROSCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230190726-A1 | COMPOSITIONS AND METHODS FOR TREATING NEGATIVE SYMPTOMS IN NON-SCHIZOPHRENIC PATIENTS | MINERVA NEUROSCIENCES, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-4070794-A2 | METHODS OF USE CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR-MEDIATED DISORDERS | Minerva Neurosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2020041504-A1 | USE OF ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISORDERS, INCREASE NEUROPLASTICITY, AND PROMOTE NEUROPROTECTION | MINERVA NEUROSCIENCES, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| EP-3335731-A1 | USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SLEEP DISORDERS | Minerva Neurosciences, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180155318-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | CYRENAIC PHARMACEUTICALS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180153871-A1 | COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA | MINERVA NEUROSCIENCES, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9730920-B2 | Compositions and methods for treating schizophrenia | MINERVA NEUROSCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170042877-A1 | COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA | MINERVA NEUROSCIENCES, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20160354357-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS | CYRENAIC PHARMACEUTICALS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9458130-B2 | Compositions and methods for treating schizophrenia | MINERVA NEUROSCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160152597-A1 | COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA | MINERVA NEUROSCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20130274289-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | CYRENAIC PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| EP-1260512-B1 | NOVEL CYCLIC AMIDE DERIVATIVES | MITSUBISHI PHARMA CORP (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153871-A1 | COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA | GRIN2C, HTR2C, COMT | HTR1A 16/4885HTR2A 14/4885TMEM97 2177/4885 |
| US-20230190726-A1 | COMPOSITIONS AND METHODS FOR TREATING NEGATIVE SYMPTOMS IN NON-SCHIZOPHRENIC PATIENTS | GBA2, NEFM, SLC6A3 | HTR1A 184/4885HTR2A 161/4885TMEM97 2511/4885 |
| US-20180155318-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | CHAT, GRIN2A, GRIN2C | HTR1A 423/4885HTR2A 159/4885TMEM97 1376/4885 |
| US-20230201184-A1 | COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA | GRIN2C, HTR2C, DBH | HTR1A 19/4885HTR2A 14/4885TMEM97 1984/4885 |
| US-20160152597-A1 | COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA | GRIN2C, HTR2C, COMT | HTR1A 16/4885HTR2A 14/4885TMEM97 2177/4885 |
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR1A 79/4885HTR2A 153/4885TMEM97 10/4885 |
| US-20160354357-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS | SIGMAR1, CNR2, HCRTR2 | HTR1A 28/4885HTR2A 4/4885TMEM97 31/4885 |
| US-20170042877-A1 | COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA | GRIN2C, HTR2C, COMT | HTR1A 16/4885HTR2A 14/4885TMEM97 2177/4885 |
| US-20130274289-A1 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | CHAT, GRIN2A, GRIN2C | HTR1A 423/4885HTR2A 159/4885TMEM97 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.